资讯

PharmExec25 分钟
FDA Approves Apellis’ Empaveli for C3 Glomerulopathy, Primary Immune Complex ...
Approval is based on results from the Phase III VALIANT trial (NCT05067127), in which Empaveli demonstrated a 68% reduction ...